Stallcup K C, Liu Y N, Dorf M E, Mescher M F
J Immunol. 1986 Apr 15;136(8):2723-8.
Previous studies have shown that plasma membranes of murine lymphocytes and lymphoid tumor cells can reversibly inhibit the growth of both normal and transformed lymphocytes. The inhibitor can be extracted with organic solvents and has properties consistent with it being a lipid or lipid-like component of the membrane. This report identifies a series of cloned macrophage hybridoma cell lines, obtained by fusion of splenic adherent cells and the P388D1 line, which have very high levels of lipid-like growth-inhibitory molecules. Furthermore, a survey of seven cloned lines indicated that the macrophages fell into two distinct groups with regard to their level of growth-inhibitory activity. Group 1 lines had little or no inhibitory activity when cells were examined for their effect on a B lymphocyte proliferative response. Organic extracts from these macrophages had inhibitory activity (on a per cell basis) comparable to that seen with extracts of the P388D1 parental cell line and lymphoid tumor cells. In contrast, relatively low numbers of Group 2 macrophages could profoundly inhibit B macrophage proliferation. The growth-inhibitory activity was quantitatively recovered in organic extracts of the macrophages. Although the precise nature of the lipid moiety remains undefined, the data argue against the involvement of oxidized cholesterol. These findings indicate that lipid-like inhibitors of cell growth are present and functional in these macrophage cell lines. In addition, the results demonstrate that the inhibitory activity found in plasma membranes and liposomes is present and active in the membranes of intact cells, which is in contrast to the possibility that the inhibitor is an artifact generated during subcellular fractionation. Thus, the inhibitor is likely to have a physiologic role in growth control and in macrophage-mediated immunoregulation, probably acting via a mechanism involving cell-cell contact.
先前的研究表明,小鼠淋巴细胞和淋巴样肿瘤细胞的质膜能够可逆地抑制正常淋巴细胞和转化淋巴细胞的生长。该抑制剂可用有机溶剂提取,其性质表明它是膜的一种脂质或类脂质成分。本报告鉴定了一系列通过脾粘附细胞与P388D1细胞系融合获得的克隆巨噬细胞杂交瘤细胞系,这些细胞系具有非常高水平的类脂质生长抑制分子。此外,对七个克隆系的调查表明,巨噬细胞在生长抑制活性水平方面分为两个不同的组。当检测细胞对B淋巴细胞增殖反应的影响时,第1组细胞系几乎没有或没有抑制活性。这些巨噬细胞的有机提取物具有(基于每个细胞)与P388D1亲本细胞系和淋巴样肿瘤细胞提取物相当的抑制活性。相比之下,相对少量的第2组巨噬细胞能够显著抑制B巨噬细胞的增殖。巨噬细胞的有机提取物中可定量回收生长抑制活性。尽管脂质部分的确切性质仍未明确,但数据表明氧化胆固醇不参与其中。这些发现表明,细胞生长的类脂质抑制剂存在于这些巨噬细胞系中并具有功能。此外,结果表明,在质膜和脂质体中发现的抑制活性存在于完整细胞的膜中并具有活性,这与抑制剂是亚细胞分级分离过程中产生的人为产物的可能性相反。因此,该抑制剂可能在生长控制和巨噬细胞介导的免疫调节中具有生理作用,可能通过涉及细胞间接触的机制发挥作用。